Baird downgraded Intra-Cellular (ITCI) to Neutral from Outperform with a $132 price target after Johnson & Johnson (JNJ) agreed to acquire all outstanding shares of Intra-Cellular for $132 per share in cash.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI:
- J&J to acquire Intra-Cellular, Clearwater to buy Enfusion: Morning Buzz
- Biotech Alert: Searches spiking for these stocks today
- Intra-Cellular downgraded to Neutral from Overweight at Cantor Fitzgerald
- Intra-Cellular downgraded to Hold from Buy at Needham
- Intra-Cellular downgraded to Equal Weight from Overweight at Morgan Stanley